DCF — MARSHALL MEDICAL CENTERS SOUTH
Enterprise Value: $-200.3M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-200.3M
Enterprise Value
$-65.6M
PV of Cash Flows
$-134.7M
PV of Terminal Value
$-216.9M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $192.5M | $-11.2M | -6.0% | $-19.4M | $-17.6M |
| Year 2 | $198.2M | $-9.6M | -5.0% | $-18.0M | $-14.9M |
| Year 3 | $204.2M | $-7.8M | -4.0% | $-16.5M | $-12.4M |
| Year 4 | $210.3M | $-7.0M | -3.0% | $-15.9M | $-10.9M |
| Year 5 | $216.6M | $-6.7M | -3.0% | $-15.9M | $-9.9M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-200.3M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$186.9M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.06343700088921332
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5